These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 3028619

  • 1. Phase I study of epirubicin given on a weekly schedule.
    Snyder R, Bishop J, Brodie G, Burns W, Coates A, Levi J, Raghavan D, Schwarz M, Tattersall M, Thomson D.
    Cancer Treat Rep; 1987 Mar; 71(3):273-6. PubMed ID: 3028619
    [Abstract] [Full Text] [Related]

  • 2. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Mar; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 3. [A phase II study of epirubicin in advanced lung cancer].
    Furuse K, Fukuoka M, Yamamoto M, Kawahara M, Tsuruta M, Kodama N, Arai R, Hayashi S, Kiyota M, Kubota K.
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2835-40. PubMed ID: 3019252
    [Abstract] [Full Text] [Related]

  • 4. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C, Biesma B, Postmus PE, Giaccone G, Schramel FM, Smit EF.
    Br J Cancer; 2001 Nov 16; 85(10):1456-61. PubMed ID: 11720428
    [Abstract] [Full Text] [Related]

  • 5. [Phase II study of epirubicin on breast cancer: a cooperative group study].
    Tominaga T, Kitamura M, Nomura Y, Abe O, Enomoto K, Ikeda T, Izuo M, Iino Y, Taguchi T, Tamura K.
    Gan To Kagaku Ryoho; 1986 Jun 16; 13(6):2187-92. PubMed ID: 3459397
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
    Focan C, Graas MP, Beauduin M, Canon JL, Salmon JP, Jerusalem G, Focan-Henrard D, Lobelle JP, Schallier D.
    Anticancer Res; 2005 Jun 16; 25(2B):1211-7. PubMed ID: 15865068
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer.
    Nishio M, Ohata M, Kobayashi H, Suruda T, Uetani K, Funasako M, Nishio K, Sasaki Y, Saijo N.
    Jpn J Clin Oncol; 1993 Oct 16; 23(5):284-90. PubMed ID: 8230753
    [Abstract] [Full Text] [Related]

  • 13. A phase II study of epirubicin in acute leukemia: a cooperative group study.
    Sampi K, Masaoka T, Shirakawa S, Shirai T, Abe T, Shibata H, Umeda M, Kobayashi T, Sugiyama H, Toki H.
    Anticancer Res; 1987 Oct 16; 7(1):29-31. PubMed ID: 3471173
    [Abstract] [Full Text] [Related]

  • 14. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G, Spielmann M, Dieras V, Tubiana-Hulin M, Bonneterre J, Pouillart P, Kayitalire L, Guastalla JP, Graffand N, Garet F, Dumortier A, Pellae-Cosset B.
    Semin Oncol; 1997 Feb 16; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [Abstract] [Full Text] [Related]

  • 15. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA, Hoffman PC, Drinkard LC, Watson S, Samuels BL, Golomb HM, Vokes EE.
    Semin Oncol; 1996 Apr 16; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [Abstract] [Full Text] [Related]

  • 16. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 16; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 17. [A phase II study of epirubicin in malignant lymphoma].
    Masaoka T, Shibata H, Sampi K, Hirota Y, Yoshida Y, Chiba Y, Shirakawa S, Kobayashi T, Toki H, Tamura K.
    Gan To Kagaku Ryoho; 1986 Aug 16; 13(8):2606-11. PubMed ID: 3461747
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
    Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F, Bonadonna G.
    Cancer Treat Rep; 1986 Feb 16; 70(2):261-6. PubMed ID: 3456271
    [Abstract] [Full Text] [Related]

  • 19. [A phase I trial of 4'-epiadriamycin].
    Ogawa M, Ikeda K, Inagaki J, Horikoshi N, Inoue K, Nakada K, Usui N, Okada Y, Adachi K, Tada A.
    Gan To Kagaku Ryoho; 1984 Apr 16; 11(4):926-9. PubMed ID: 6586111
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.